hVIVO Dividends and Buybacks

Dividend criteria checks 0/6

hVIVO is a dividend paying company with a current yield of 1.02%.

Key information

1.0%

Dividend yield

-0.07%

Buyback Yield

Total Shareholder Yield	1.0%
Future Dividend Yield	1.3%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	UK£0.002
Payout ratio	8%

Recent dividend and buyback updates

No updates

Recent updates

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Jan 26

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

Jan 03

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: HVO is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: HVO is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.

Dividend Yield vs Market

hVIVO Dividend Yield vs Market

How does HVO dividend yield compare to the market?
Segment	Dividend Yield
Company (HVO)	1.0%
Market Bottom 25% (GB)	2.1%
Market Top 25% (GB)	5.8%
Industry Average (Life Sciences)	0.7%
Analyst forecast (HVO) (up to 3 years)	1.3%

Notable Dividend: HVO's dividend (1.02%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (2.15%).

High Dividend: HVO's dividend (1.02%) is low compared to the top 25% of dividend payers in the UK market (5.77%).

Earnings Payout to Shareholders

Earnings Coverage: HVO is not paying a notable dividend for the UK market.

Cash Payout to Shareholders

Cash Flow Coverage: HVO is not paying a notable dividend for the UK market.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 01:46
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

hVIVO plc is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Simms	Arden Partners Plc.
Andrew Murray Darley	Cavendish
Stuart Harris	Cavendish

hVIVO Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

Price target increased by 7.2% to UK£0.36

hVIVO plc, Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

New minor risk - Share price stability

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

hVIVO plc Signs £6.3 Million Human Challenge Study Model

At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

Now 22% undervalued

hVIVO plc Announces Publication of Imutex Phase I Data

Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought UK£300k worth of stock

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

New 90-day high: UK£0.28

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Calculating The Fair Value Of Open Orphan plc (LON:ORPH)

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

Analysts lower EPS estimates to -UK£0.021

New 90-day high: UK£0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020